JADE101

Monoclonal antibody

Phase 3underway

Evidence outlook · registrational

IgA Nephropathy: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-06.

Featured evidence outside this drug's tracked markets:NCT07059312 · Healthy Volunteers · Phase 1 · completed · ungraded

Company guidance: interim data expected in 2027 (Jade Biosciences, Inc., 10 Aug 2026). “Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
IgA Nephropathy
NCT07902817 · Jade Biosciences, Inc.
2026-12 – 2030-09 · IgA Nephropathy (IgAN)
What this study did
Phase 2 (1)
IgA Nephropathy
Phase 1 (2)
Other / comorbidity
NCT07525947 · Jade Biosciences, Inc.
2026-05-01 – 2027-05 · Healthy Volunteers (HV)
What this study did
NCT07059312 · Jade Biosciences, Inc.
2025-08-17 – 2026-10-21 · Healthy Volunteers
What this study did

Competitive landscape

Other APRIL (A Proliferation-Inducing Ligand, TNFSF13) drugs

Zigakibart. Compare all 2 APRIL (A Proliferation-Inducing Ligand, TNFSF13) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for IgA Nephropathy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
JADE101: this drugPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
AtaciceptApprovedProtein / enzyme therapeuticBLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand)Partial signalFeatured results are non-efficacy only in this race
Atrasentan (Vanrafia)ApprovedSmall moleculeEndothelin A receptorPartial signal
NCT04573478: Primary (interim, first 270 patients): 24-hour UPCR change at week 36, atrasentan -38.1% vs placebo -3.1%; between-group difference -36.1 percentage points (95% CI -44.6 to -26.4), P<0.001
Budesonide (targeted-Release) (TARPEYO / Nefecon)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT06291376: Primary 1, change in 24-hour UPCR at week 34 (prespecified interim analysis), ravulizumab vs placebo: the sponsor reports a statistically significant and clinically meaningful reduction, met; figures not yet published. Primary 2, change in eGFR at week 106: not yet reported; the trial is ongoing.
Sparsentan (Filspari)ApprovedSmall moleculeAngiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Partial signalFeatured results are non-efficacy only in this race
FelzartamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
PovetaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
SefaxersenPhase 3RNA / oligonucleotideComplement factor B (CFB)Partial signal
NCT05797610: Prespecified interim analysis: statistically significant reduction in proteinuria (24-hour UPCR) vs placebo at week 37 (2026-09-23).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 1/2Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
ARO-CFBPhase 1RNA / oligonucleotideComplement factor B (CFB) mRNAnot yet gradedNo reviewed efficacy summary in this indication
Opemalirsen
Phase 1(overall)
RNA / oligonucleotide—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow JADE101 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
Phase 1Healthy Volunteers (HV)Recruiting
Est. primary completion 2027-05 · NCT07525947 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 2IgA NephropathyRecruiting
Est. primary completion 2029-01 · NCT07541287 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3IgA NephropathyRecruiting
Est. primary completion 2029-06 · NCT07902817 · CT.gov ↗
What to watch

See the full readout calendar ↗